Internal medicine, Endocrinology, Type 2 diabetes, Insulin and Insulin resistance are his primary areas of study. Allan Vaag has included themes like Diabetes mellitus, Regulation of gene expression and Gene expression in his Internal medicine study. The concepts of his Diabetes mellitus study are interwoven with issues in Glucose transporter, Heritability, Myocardial infarction and Genetic predisposition.
His work deals with themes such as Epigenetics and DNA methylation, which intersect with Endocrinology. His Type 2 diabetes research includes elements of Metformin, Genome-wide association study, Type 2 Diabetes Mellitus and Glucose homeostasis. In his work, Gastric inhibitory polypeptide is strongly intertwined with Glucagon-like peptide-1, which is a subfield of Insulin.
His main research concerns Internal medicine, Endocrinology, Type 2 diabetes, Insulin and Insulin resistance. His research integrates issues of Diabetes mellitus, Type 2 Diabetes Mellitus and DNA methylation in his study of Internal medicine. His Diabetes mellitus research includes themes of Offspring, Pregnancy and Gestational diabetes.
In his research, Low birth weight and Physiology is intimately related to Birth weight, which falls under the overarching field of Endocrinology. His Type 2 diabetes study integrates concerns from other disciplines, such as Body mass index, Gastroenterology, Randomized controlled trial, Metabolic syndrome and Epigenetics. His research ties Metabolism and Insulin together.
Allan Vaag mostly deals with Internal medicine, Type 2 diabetes, Gestational diabetes, Insulin resistance and Endocrinology. His works in Body mass index, Insulin, Clinical trial, Odds ratio and Concomitant are all subjects of inquiry into Internal medicine. His Type 2 diabetes research is classified as research in Diabetes mellitus.
His Gestational diabetes research also works with subjects such as
Allan Vaag mainly focuses on Internal medicine, Type 2 diabetes, Gestational diabetes, Endocrinology and Offspring. His study in Autophagy extends to Internal medicine with its themes. The Type 2 diabetes study combines topics in areas such as Body mass index, Physical therapy, Birth weight and Cohort study.
His Endocrinology study typically links adjacent topics like DNA methylation. His Offspring research is multidisciplinary, incorporating elements of Diabetes mellitus and Fetus. His study in Diabetes mellitus is interdisciplinary in nature, drawing from both Blood pressure and Cohort.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Epigenetic differences arise during the lifetime of monozygotic twins
Mario F. Fraga;Esteban Ballestar;Maria F. Paz;Santiago Ropero.
Proceedings of the National Academy of Sciences of the United States of America (2005)
Interleukin-1-receptor antagonist in type 2 diabetes mellitus.
Claus M Larsen;Mirjam Faulenbach;Allan Vaag;Allan Vaag;Aage Vølund.
The New England Journal of Medicine (2007)
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
D. Russell-Jones;A. Vaag;O. Schmitz;B. K. Sethi.
Heritability of type II (non-insulin-dependent) diabetes mellitus and abnormal glucose tolerance--a population-based twin study.
P. Poulsen;K. Ohm Kyvik;A. Vaag;H. Beck-Nielsen.
Diabetes Patients Requiring Glucose-Lowering Therapy and Nondiabetics With a Prior Myocardial Infarction Carry the Same Cardiovascular Risk: A Population Study of 3.3 Million People
Tina Ken Schramm;Gunnar H. Gislason;Lars Køber;Søren Rasmussen.
Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non-insulin-dependent) diabetic patients.
M. A. Gall;P. Rossing;P. Skøtt;P. Damsbo.
Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study.
Tina Ken Schramm;Gunnar Hilmar Gislason;Allan Vaag;Jeppe Nørgaard Rasmussen.
European Heart Journal (2011)
Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia.
Johan Rung;Stéphane Cauchi;Anders Albrechtsen;Lishuang Shen;Lishuang Shen.
Nature Genetics (2009)
Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus
Bianca Hemmingsen;Søren S Lund;Christian Gluud;Allan Vaag.
Cochrane Database of Systematic Reviews (2015)
Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes
Claus M. Larsen;Mirjam Faulenbach;Allan Vaag;Jan A. Ehses.
Diabetes Care (2009)
Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking h-index is inferred from publications deemed to belong to the considered discipline.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: